Aquestive Therapeutics (AQST) Net Cash Flow (2017 - 2026)

Aquestive Therapeutics' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$10.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 261.2% year-over-year to -$10.4 million in Q1 2026; TTM through Mar 2026 was $42.1 million, a 258.52% increase from a year earlier, with the FY2025 full-year figure at $49.6 million, up 4.09% from the prior year.
• Net Cash Flow slipped to -$10.4 million in Q1 2026 per AQST's latest filing, from -$7.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $71.3 million in Q1 2024 and bottomed at -$13.3 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$2.9 million (2025), against an average of $4.9 million.
• Biggest YoY gain for Net Cash Flow was 18342.46% in 2024; the steepest drop was 582.75% in 2024.
• Year by year, Net Cash Flow stood at $8.6 million in 2022, then tumbled by 112.12% to -$1.0 million in 2023, then plunged by 507.37% to -$6.3 million in 2024, then fell by 24.37% to -$7.9 million in 2025, then tumbled by 32.19% to -$10.4 million in 2026.
• Per Business Quant, the three latest AQST Net Cash Flow figures stand at -$10.4 million (Q1 2026), -$7.9 million (Q4 2025), and $68.5 million (Q3 2025).